Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.

× No keyword cloud information.

17 in total

Review 1. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors: Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal: Oncologist Date: 2016-06-27

Review 2. Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors: Emily H Castellanos; Leora Horn
Journal: Oncologist Date: 2016-04-06

3. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.

Authors: Fang Wu; Junhe Li; Changchen Jang; Janfeng Wang; Jianping Xiong
Journal: Int J Clin Exp Pathol Date: 2014-09-15

Review 4. Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer.

Authors: Ourania Romanidou; Lorenza Landi; Federico Cappuzzo; Raffaele Califano
Journal: Ther Adv Med Oncol Date: 2016-02-16 Impact factor: 8.168

5. Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors.

Authors: Elena Poddubskaya; Alexey Bondarenko; Alexander Boroda; Evgenia Zotova; Alex Glusker; Svetlana Sletina; Luidmila Makovskaia; Philipp Kopylov; Marina Sekacheva; Alexey Moisseev; Madina Baranova
Journal: Front Oncol Date: 2019-10-15 Impact factor: 6.244

Review 6. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Authors: Saoirse O Dolly; Dearbhaile C Collins; Raghav Sundar; Sanjay Popat; Timothy A Yap
Journal: Drugs Date: 2017-05 Impact factor: 9.546

7. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Authors: Paul J Hampel; Wei Ding; Timothy G Call; Kari G Rabe; Saad S Kenderian; Thomas E Witzig; Eli Muchtar; Jose F Leis; Asher A Chanan-Khan; Amber B Koehler; Amie L Fonder; Susan M Schwager; Susan L Slager; Tait D Shanafelt; Neil E Kay; Sameer A Parikh
Journal: Leuk Lymphoma Date: 2019-04-24

Review 8. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

Authors: Justin F Gainor; Alice T Shaw
Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544

9. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.

Authors: Aaron S Meyer; Miles A Miller; Frank B Gertler; Douglas A Lauffenburger
Journal: Sci Signal Date: 2013-08-06 Impact factor: 8.192

10. Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression.

Authors: Leonidas Apostolidis; Jan Pfeiffenberger; Daniel Gotthardt; Boris Radeleff; Arianeb Mehrabi; Peter Schemmer; Dirk Jäger; Peter Schirmacher; Wolfgang Stremmel; Henning Schulze-Bergkamen; Christoph Springfeld; Karl Heinz Weiss
Journal: Gastrointest Tumors Date: 2018-04-11